Delivery Order SPE2DB24D1104-SPE2DB25FXWQ6

Award Date 1/17/25
Potential Completion Date 1/21/25
Potential Value $10K
Ultimate Awardee
Not listed
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Competed under SAP
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Conshohocken, PA 19428, USA
Solicitation Procedures
Simplified Acquisition
Number Of Offers Received
Not listed
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
This federal contract award was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $4,821.98 firm fixed-price delivery order is for the supply of PULMOZYME 1 MG/ML AMPUL 2.5ML, a pharmaceutical product used in medical treatment. The contract has an ultimate completion date of October 17, 2024. Amerisourcebergen holds a significant Indefinite Delivery Contract (IDC) with the DLA Troop Support...
This contract award is to Amerisourcebergen Drug Corporation's Corporate Office Division, a major pharmaceutical distributor in the United States. The contract, awarded by the Defense Logistics Agency (DLA) Troop Support Medical, is a $2,817.41 Firm Fixed Price Delivery Order for the supply of PULMOZYME 1 MG/ML AMPUL 2.5ML. The contract has an ultimate completion date of September 13, 2024. This contract award is not associated with a set-aside program. Amerisourcebergen holds a significant...
This federal contract award was made by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor, for the supply of PULMOZYME 1 MG/ML AMPUL 2.5ML, a prescription medication. The award, valued at $2,410.99, is a firm-fixed-price delivery order with a completion date of June 13, 2024. Amerisourcebergen holds a significant Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, valued up to $999,999,999.00, which serves as the primary...
This is a federal contract award from the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract, valued at $22,139.40, is for the delivery of PULMOZYME 1 MG/ML AMPUL 2.5ML, a pharmaceutical product. The contract type is a Delivery Order, with a Firm Fixed Price pricing structure, and an ultimate completion date of January 3, 2025. The contract is not designated as a set-aside. AmerisourceBergen holds a...
This federal contract award was issued by the Defense Logistics Agency (DLA) Troop Support Medical to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $7,488.59 firm fixed-price delivery order is for the supply of PULMOZYME 1 MG/ML AMPUL 2.5ML, a specialty medication. The contract has a completion date of December 9, 2024. Amerisourcebergen holds a significant $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical,...
This federal contract award, valued at $10,020.72, was issued by the Defense Logistics Agency (DLA) Troop Support Medical to Amerisourcebergen Drug Corp's Corporate Office Division. The contract is for the delivery of Pulmozyme 1 mg/ml ampul 2.5 ml, a pharmaceutical product. Amerisourcebergen holds a larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, valued up to $999,999,999.00 through December 31, 2025. This single-award IDC serves as the primary vehicle for...
This federal contract award to AmerisourceBergen Drug Corp, a major pharmaceutical distributor, is for the supply of Pulmozyme 1 mg/ml ampul 2.5 ml, a specialty medication. The $5,231 firm fixed-price delivery order was issued by the Defense Logistics Agency (DLA), a defense agency, and has an ultimate completion date of October 28, 2024. The contract is not designated as a set-aside. AmerisourceBergen holds a $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical,...
This federal contract award was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor, for the supply of Pulmozyme 1 mg/ml ampul 2.5 ml. The $6,929.36 firm fixed-price delivery order has an ultimate completion date of April 20, 2023. The contract is not designated as a set-aside award. Amerisourcebergen holds a $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical through November 2026, which serves as a...
This is a federal contract award from the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $24,339.01 firm fixed price delivery order is for the supply of Pulmozyme 1 mg/ml ampul 2.5 ml, a medication primarily used to treat cystic fibrosis. The contract has an ultimate completion date of February 10, 2025 and was awarded on February 7, 2025. AmerisourceBergen holds a significant $999,999,999 Indefinite...
This federal contract award was made by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor, for the delivery of Pulmozyme 1 mg/mL ampules in 2.5 mL quantities. The contract is a Delivery Order with a Firm Fixed Price type, valued at $8,017.10, and has an ultimate completion date of May 29, 2024. Amerisourcebergen holds a larger Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical valued at up to $999,999,999.00 through...
  • SPE2DB24D1104
    Indefinite Delivery Contract
  • SPE2DB24D1104-SPE2DB25FXWQ6
    Delivery Order

This is a federal contract award from the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the delivery of PULMOZYME 1 MG/ML AMPUL 2.5ML, a medical product, with a ceiling value of $10,472.72. The contract is a Firm Fixed Price Delivery Order, with a period of performance through January 21, 2025.

AmerisourceBergen holds a significant Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, valued at $999,999,999 and running through November 2026. This IDC serves as a primary vehicle for providing a comprehensive range of pharmaceutical products and medical supplies to support military healthcare programs globally. The company also maintains a separate IDC with the Department of Justice Federal Bureau of Investigation, valued at $750,000 through May 2024, which covers similar medical products and prescription drugs. These IDCs enable efficient government procurement of essential pharmaceutical and medical supplies, serving the healthcare needs of military personnel, veterans, and other federal beneficiaries.

The contract award does not have a set-aside designation, indicating open competition.

Generated 4/18/25, 2:02 PM